Joshua Brody, Director of the Lymphoma Immunotherapy Program at Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“Adding Bispecific, Antibody immunotherapy to gentle chemo puts 96% of Follicular Lymphoma PATIENTS into remission!
Congratulations to Dr Vitolo and the EPCORE Team esp Mount Sinai NYC! Thanks Hemasphere EHA, EHA Hematology for sharing this great result!”
Title: First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma
Authors: Umberto Vitolo, Lorenzo Falchi, Per-Ola Andersson, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Jacob H. Christensen, Michael R. Clausen, Alexander Fosså, Pilar G. Prieto, Eliza A. Hawkes, Judit M. Jørgensen, Yasmin H. Karimi, Catharina Lewerin, Joost S. P. Vermaat, Björn E. Wahlin, Poliana Patah, Christopher Morehouse, Malene Risum, Zhu Li, Jennifer Marek, Joshua D. Brody.
Read The Full Article.
